Agreed. Mark has a significant number of engagements...for sure. The only real confirmation as far as I'm concerned, is the Alphazme deal, where DYAI now owns a piece of the company. They are private and growing (see article..https://www.palmbeachpost.com/story/business/2021/03/11/beacon-pharmaceutical-incubator-plan-advances-alphazyme-expands/4628102001/ So, DYAI is currently worth at a minimum, its cash, PLUS the imputed value of the private holdings of Alphazyme. The rest is all a high wire act by Emelfarb. The question is, if Mark was out of the picture, who would buy this company/patents, and what is the real value here? I don't have a clue. Other than Alphazyme, there is not 1 company to come forward and demonstrate confidence.
News 
Market Data 
Discover 
